CorpDigest
Gilead Sciences, Inc.
Leadership History
4 leaders · Full leadership timeline
Last reviewed: 2026-06-08 · By Swet Parvadiya
Gilead Sciences, Inc. generated $28.5 billion in FY2024 net sales, operating as a dominant force in virology and a rapidly scaling oncology powerhouse that commands an 82% gross margin by focusing exclusively on high-margin patented therapeutics. The company's strategic identity was defined through a series of transformational acquisitions, most notably the $11 billion purchase of Pharmasset to secure the hepatitis C platform, and the $21 billion acquisition of Immunomedics to establish a dominant position in ADCs with Trodelvy. This pivot has resulted in a highly diversified portfolio where growth is driven by the HIV franchise, anchored by Biktarvy ($13.8 billion in FY2024 sales), and the rapidly scaling oncology portfolio, led by Trodelvy and Yescarta. With approximately 18,000 employees and a market capitalization of $135 billion, Gilead allocates $4.5 billion annually to R&D, funding a pipeline of over 50 clinical projects and enabling aggressive acquisitions in oncology and cell therapy. The company's future depends on its ability to execute a 5-8% constant currency sales CAGR through 2030, a target that requires the successful launch of next-generation assets like lenacapavir and the continuous expansion of its dominant position in HIV and oncology to offset the impending patent cliffs of its core franchises.
Chief Executive Officer
Milligan assumed the role of CEO in January 2024, bringing over 20 years of experience at Gilead. He previously served as Executive Vice President of Corporate Operations, where he oversaw the commercial launch of Biktarvy and the integration of the Kite Pharma and Immunomedics acquisitions.
Executive Vice President, Chief Financial Officer
Dickinson manages the financial aspects of the company's diversified portfolio, including the capital allocation strategy for the massive R&D and manufacturing investments. He played a key role in maintaining the company's strong credit rating and investor confidence during the transition post-Veklury.
President, Global Commercial Organization
Mercier is responsible for driving the company's global commercial strategy, including the launch of Trodelvy and Yescarta and the navigation of the complex PBM rebate landscape in the US. She has led the expansion of the sales force and the implementation of data-driven commercial execution strategies.
Former Chief Executive Officer
O'Day served as CEO for a brief period in 2023, overseeing the initial stages of the company's transition to a diversified biopharmaceutical enterprise before stepping down to pursue other opportunities.
The single most dangerous threat to Gilead Sciences, Inc.'s margin and market share right now is the impending patent cliff for its core HIV franchise, specifically the composition-of-matter and formulation patents protecting Biktarvy that begin to expire in the early 2030s. Biktarvy generated $13.8 billion in FY2024 sales, making it the company's largest single product and the primary engine of corporate cash flow, but the loss of exclusivity will trigger immediate and severe revenue erosion as generic manufacturers and specialized HIV companies introduce lower-cost alternatives. This patent cliff is not an isolated event; it is a structural vulnerability of the innovative pharmaceutical model, and Gilead faces subsequent exclusivity losses for other key assets, including Descovy and certain legacy HIV regimens, in the coming years. Concurrently, the company is navigating intense competitive pressure in the HIV prevention space from Merck's islatravir, a novel nucleoside reverse transcriptase translocase inhibitor (NRTTI) that offers the potential for once-monthly oral dosing or even less frequent administration, a modality that could disrupt the current standard of daily oral PrEP dominated by Gilead's Truvada and Descovy. While Gilead's lenacapavir has demonstrated unprecedented efficacy as a twice-yearly injectable for PrEP, the commercial rollout of this asset requires the establishment of a specialized injection infrastructure and faces significant pricing and reimbursement hurdles in the global market. The competitive landscape in oncology has also become increasingly crowded and complex. In the ADC space, Trodelvy faces relentless competition from AstraZeneca's Enhertu, which has demonstrated superior efficacy in certain breast cancer subtypes, and from a new wave of next-generation ADCs targeting HER2, TROP2, and other receptors developed by Pfizer, Seagen (now part of Pfizer), and Daiichi Sankyo. In the CAR-T cell therapy space, Yescarta is locked in a fierce battle with Bristol Myers Squibb's Abecma and Carvykti, while simultaneously facing the long-term threat of allogeneic 'off-the-shelf' CAR-T therapies developed by Allogene Therapeutics and CRISPR Therapeutics, which could potentially eliminate the complex, expensive autologous manufacturing process that currently defines the Gilead oncology model. The company's response to these challenges has been to pivot aggressively toward next-generation modalities, including bispecific antibodies, targeted protein degraders, and novel cell therapies, but this pivot requires massive capital expenditure and carries high binary clinical risk. The discontinuation of magrolimab in 2023 following Phase III trial failures in myelodysplastic syndromes resulted in a significant write-down and highlighted the unforgiving nature of late-stage clinical development. The company must also manage the operational complexity of a massively expanded manufacturing footprint. The scale-up of Yescarta production requires the continuous addition of new clean room suites and the optimization of the lentiviral vector supply chain, a logistical challenge that exposes the company to production delays, regulatory inspections, and raw material shortages. Any interruption in the supply of the specialized reagents required for CAR-T manufacturing would immediately halt the production of Yescarta, resulting in lost revenue and potential damage to the company's reputation among oncologists who rely on consistent drug availability for their patients. Additionally, the company faces significant headwinds from the US Inflation Reduction Act, which has empowered Medicare to negotiate drug prices. While the initial rounds of negotiation targeted older, high-expenditure drugs, the political momentum to include newer, high-cost oncology and virology therapies in future negotiations is growing rapidly, threatening to compress the 82% gross margin that currently defines the company's financial profile. The legal and regulatory battles surrounding the pricing of HIV therapies in the US represent another critical challenge. Gilead has faced intense scrutiny from state attorneys general and federal regulators regarding its pricing strategies and rebate agreements with PBMs, allegations that the company has consistently denied but which have resulted in significant legal fees and reputational damage. The existence of a parallel, low-cost supply chain for HIV pre-exposure prophylaxis, driven by the availability of generic Truvada and the compounding of oral antiretrovirals, has permanently altered patient and payer expectations regarding the pricing of HIV prevention therapies, making it increasingly difficult for Gilead to maintain its premium list prices for Descovy and lenacapavir without facing intense public and political backlash.